🇺🇸 Glulisine Insulin in United States

26 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Acute Myocardial Infarction — 5 reports (19.23%)
  2. Cardio-Respiratory Arrest — 5 reports (19.23%)
  3. Atrial Septal Defect — 2 reports (7.69%)
  4. Caesarean Section — 2 reports (7.69%)
  5. Decreased Appetite — 2 reports (7.69%)
  6. General Physical Health Deterioration — 2 reports (7.69%)
  7. Lip Disorder — 2 reports (7.69%)
  8. Maternal Drugs Affecting Foetus — 2 reports (7.69%)
  9. Oral Disorder — 2 reports (7.69%)
  10. Premature Baby — 2 reports (7.69%)

Source database →

Glulisine Insulin in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Glulisine Insulin approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Glulisine Insulin in United States?

Emory University is the originator. The local marketing authorisation holder may differ — check the official source linked above.